<DOC>
	<DOC>NCT00220285</DOC>
	<brief_summary>The purpose of this study is to investigate the antitumor effect and safety of the product for relapsed or refractory indolent B-cell non-Hodgkin's lymphomas.</brief_summary>
	<brief_title>Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Platelet counts of &gt;/= 100,000/mm3 Absolute neutrophil counts of &gt;/= 1,200/mm3 Bone marrow involvement &lt; 25% Patients who received hematopoietic stem cell transplantation, including bone marrow transplantation, peripheral blood stem cell transplantation, etc. Patients presenting with marked bone marrow hypocellularity (any suspected bone marrow hypocellularity should be confirmed by bone marrow biopsy) Patients with previous myocardial infarction within the past 1 year, with heart disease that requires treatment or with pulmonary dysfunction Patients with serious concomitant diseases (cardiac failure, renal failure, etc.)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Antigen</keyword>
	<keyword>CD20</keyword>
</DOC>